Noramco, a global active pharmaceutical ingredients (API) manufacturer specializing in controlled substances, has acquired Cambrex Drug Product Business Unit previously known as Halo Pharmaceuticals. The acquisition will provide API customers of Noramco, and its subsidiary Purisys, additional service options such as drug product formulation development, clinical and commercial drug product manufacturing, and packaging from facilities in Mirabel, Québec and Whippany, NJ. Noramco is returning to t...